Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | TLR4 | O00206 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17510318 | 1.00 | LMNA (0.33) | LMNAMAPTL3MBTL1SMN1; SMN2AR | |
| SCHEMBL4843284 | 0.88 | CA1 (0.34) | LMNA | |
| SCHEMBL16056609 | 0.77 | — | — | |
| SCHEMBL21219695 | 0.76 | LMNA (0.33) | LMNAMAPTL3MBTL1 | |
| SCHEMBL12489486 | 0.76 | LMNA (0.33) | LMNAMAPTL3MBTL1 | |
| SCHEMBL28173692 | 0.76 | LMNA (0.41) | LMNAMAPTL3MBTL1 | |
| SCHEMBL3278691 | 0.75 | L3MBTL1 (0.35) | MAPTL3MBTL1TLR4 | |
| SCHEMBL3660712 | 0.75 | LMNA (0.32) | LMNAMAPT | |
| SCHEMBL9185214 | 0.75 | GAA (0.41) | MAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL2869309 | 0.74 | ACE (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2098507-B1 | Cyclic amine compound as androgen receptor modulator | TAKEDA PHARMACEUTICAL (JP) | 2014-11-12 | — | — | EP | disclosed |
| US-8420694-B2 | Pyrrolidin-2-one derivatives as androgen receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-16 | — | — | US | disclosed |
| EP-2176220-B1 | Pyrrolidin-2-one derivatives as androgen receptor modulators | TAKEDA PHARMACEUTICAL (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-2176220-A2 | PYRROLIDIN-2-ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR | Takeda Pharmaceutical Company Limited (JP) | 2010-04-21 | — | — | EP | disclosed |
| US-20100087506-A1 | CYCLIC AMINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-2098507-A1 | CYCLIC AMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-09 | — | — | EP | disclosed |
| WO-2009020234-A2 | PYRROLIDIN-2 -ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087506-A1 | CYCLIC AMINE COMPOUND | AR, FSHR, NR5A1 | LMNA 4039/4885MAPT 4206/4885L3MBTL1 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.